References
- Smilkstein MJ, Knapp GL, Kulig KW, et al. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med. 1998;319:1557–1562.
- Daly FF, Fountain JS, Murray L, et al. Guidelines for the management of paracetamol poisoning in Australia and New Zealand – explanation and elaboration. A consensus statement from clinical toxicologists consulting to the Australasian poisons information centres. Med J Aust. 2008;188:296–301.
- Sangkuhl K, Klein T, Altman RB. PharmGKB summary: citalopram pharmacokinetics pathway. Pharmacogenet Genomics. 2011;21:769–772.
- Periti P, Mazzei T, Mini E, et al. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet. 1992;23:106–131.
- Pencharz PB, Durie PR. Pathogenesis of malnutrition in cystic fibrosis, and its treatment. Clin Nutr. 2000;19:387–394.
- Roum JH, Buhl R, McElvaney NG, et al. Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol. 1993;75:2419–2424.
- Henrion-Caude A, Flamant C, Roussey M, et al. Liver disease in pediatric patients with cystic fibrosis is associated with glutathione S-transferase P1 polymorphism. Hepatology. 2002;36:913–917.
- Hutabarat RM, Unadkat JD, Kushmerick P, et al. Disposition of drugs in cystic fibrosis. III. Acetaminophen. Clin Pharmacol Ther. 1991;50:695–701.
- Linden CH, Rumack BH. Acetaminophen overdose. Emerg Med Clin N Am. 1984;2:103–119.
- Vliegenthart AD, Shaffer JM, Clarke JI, et al. Comprehensive microRNA profiling in acetaminophen toxicity identifies novel circulating biomarkers for human liver and kidney injury. Sci Rep. 2015;5:22–15501.
- Dear JW, Clarke JI, Francis B, et al. Risk stratification after paracetamol overdose using mechanistic biomarkers: results from two prospective cohort studies. Lancet Gastroenterol Hepatol. 2018;3:104–113.